|
KMID : 1039420220560050281
|
|
Journal of Pathology and Translational Medicine
2022 Volume.56 No. 5 p.281 ~ p.288
|
|
|
Prognostic significance of BLK expression in R-CHOP treated diffuse large B-cell lymphoma
|
|
Choi So-Yeon
Lee Yoo-Jin
Choi Yun-Suk
Kim Mi-Sung
Kim Hyun-Jung
Kim Ji-Eun
Oh Suk-Joong
Chae Seoung-Wan
Cha Hee-Jeong
Jo Jae-Cheol
|
|
|
Abstract
|
|
|
Background: The aim of the present study was to evaluate the prognostic significance of B-cell lymphocyte kinase (BLK) expression for survival outcomes in diffuse large B-cell lymphoma (DLBCL) patients treated with R-CHOP.
Methods: We retrospectively analyzed the medical records of 89 patients from two tertiary referral hospitals. The expression of BLK, SYK, and CDK1 were evaluated in a semiquantitative method using an H-score, and the proportions of BCL2 and C-MYC were evaluated.
Results: A total of 89 patients received R-CHOP chemotherapy as a first-line chemotherapy. The expression rates of BLK in tumor cells was 39.2% (n = 34). BLK expression status was not significantly associated with clinical variables; however, BLK expression in tumor cells was significantly associated with the expression of both C-MYC and BCL2 (p = .003). With a median follow-up of 60.4 months, patients with BLK expression had significantly lower 5-year progression-free survival (PFS) and overall survival rates (49.8% and 60.9%, respectively) than patients without BLK expression (77.3% and 86.7%, respectively). In multivariate analysis for PFS, BLK positivity was an independent poor prognostic factor (hazard ratio, 2.208; p = .040).
Conclusions: Here, we describe the clinicopathological features and survival outcome according to expression of BLK in DLBCL. Approximately 39% of DLBCL patients showed BLK positivity, which was associated as a predictive marker for poor prognosis in patients who received R-CHOP chemotherapy.
|
|
|
KEYWORD
|
|
|
Diffuse large B-cell lymphoma, Immunohistochemistry
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|